Clinical trial · Observational
Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer
Prevalence of Alpha-1 Antitrypsin Deficiency in a Cohort of Hepatocellular Carcinoma on Non-Cirrhotic Liver Without Identified Etiologies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| multiplex digital PCR | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients Diagnosed with HCC on Non-Cirrhotic Liver
- description
- Patients Diagnosed with HCC on Non-Cirrhotic Liver
- interventionNames
- Other: multiplex digital PCR
Primary outcomes (1)
- measure
- Prevalence of Alpha-1 Antitrypsin Deficiency
- timeFrame
- 1 year
- description
- Prevalence of Alpha-1 Antitrypsin Deficiency in a Retrospective Cohort of Patients Diagnosed with HCC on Non-Cirrhotic Liver up to 1 year
Secondary outcomes (1)
- measure
- Correlation of clinico-biological parameters-including survival (years), sex, BMI, fibrosis stage, mode of diagnosis, number of tumors, tumor size (mm), metastasis, recurrence, and Edmondson score-according to AAT genotype
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients (≥18 years of age). 2. Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC). 3. Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue. 4. Signed informed consent obtained prior to participation. 5. No other known etiology or risk factors for liver disease, including: * Alcohol-related liver disease * Metabolic-associated steatohepatitis (MASH) * Viral hepatitis infections * Hemochromatosis Exclusion Criteria: 1. Minor patients (\<18 years of age). 2. HCC diagnosis not established according to standard histopathological criteria. 3. Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue. 4. No signed informed consent prior to participation. 5. Presence of other identified etiologies or known risk factors for liver disease, including: * Alcohol-related liver disease * Metabolic-associated steatohepatitis (MASH) * Viral hepatitis infections * Hemochromatosi
References
Publications (1)
- DERIVEDBeaufrere A, Leon C, Decreaker M, Possenti L, Evain M, Coilly A, Schneider CV, Feurer Z, Odou MF, Balduyck M, Payance A, Schneider KM, Bioulac P, Blanc JF, Le Bail B, Guettier C, Amintas S, Bouchecareilh M. Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort. J Clin Exp Hepatol. 2026 Jul-Aug;16(4):103545. doi: 10.1016/j.jceh.2026.103545. Epub 2026 Apr 3. PMID 42064227